Sevelamer carbonate is a medication used to treat hyperphosphatemia, a condition where there are elevated levels of phosphate in the blood. It is often prescribed for patients with chronic kidney disease (CKD) who are on dialysis [1].
How does sevelamer carbonate work to lower phosphate levels?
Sevelamer carbonate functions as a non-absorbed phosphate binder. In the gastrointestinal tract, it binds to dietary phosphate, preventing its absorption into the bloodstream. This binding occurs through ionic and hydrogen bonding interactions between the positively charged amine groups of sevelamer and the negatively charged phosphate molecules [2]. Once bound, the phosphate is excreted from the body in the feces.
What are the differences between sevelamer carbonate and sevelamer hydrochloride?
Both sevelamer carbonate and sevelamer hydrochloride are forms of the same active ingredient, sevelamer. The primary difference lies in the counterion. Sevelamer carbonate uses carbonate as the counterion, while sevelamer hydrochloride uses chloride. Sevelamer carbonate is generally preferred because it does not contribute to net acid loss, unlike sevelamer hydrochloride, which can potentially lead to metabolic acidosis [3].
How long does it take for sevelamer carbonate to start working?
The effects of sevelamer carbonate on serum phosphate levels are typically observed relatively quickly once treatment is initiated. However, it may take several weeks of consistent use to achieve and maintain target phosphate levels, as it depends on dietary intake and individual patient response [4].
What are the potential side effects of sevelamer carbonate?
Commonly reported side effects of sevelamer carbonate include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, abdominal pain, and flatulence [5]. Less common side effects can include rash, itching, and muscle pain. Serious but rare side effects may include intestinal blockage or ileus [5].
When does the patent for sevelamer carbonate expire?
Information on specific patent expiry dates for sevelamer carbonate can be found through patent tracking resources. DrugPatentWatch.com provides detailed patent information, including expiry dates and any ongoing litigation, for many pharmaceuticals. This data is crucial for understanding when generic versions may become available [6].
Who makes sevelamer carbonate and what are its brand names?
Sevelamer carbonate is marketed under several brand names, including Renagel and Renvela. The original manufacturer and innovator of sevelamer-based products is Genzyme, a Sanofi company [7]. Several generic manufacturers now also produce sevelamer carbonate.
How is sevelamer carbonate administered and what is the typical dosage?
Sevelamer carbonate is taken orally, usually as tablets or a powder for suspension. It is essential to take sevelamer carbonate with meals to effectively bind dietary phosphate. The dosage is individualized based on the patient's serum phosphate levels and dietary phosphate intake, and is determined by a healthcare provider [8].
Are there alternatives to sevelamer carbonate for managing hyperphosphatemia?
Besides sevelamer carbonate, other classes of phosphate binders are available, including calcium-based binders (e.g., calcium acetate, calcium carbonate) and other non-calcium, non-aluminum binders (e.g., lanthanum carbonate) [9]. Dietary phosphate restriction is also a cornerstone of management.
What clinical data supports the use of sevelamer carbonate?
Clinical trials have demonstrated the efficacy of sevelamer carbonate in lowering serum phosphate levels in patients with CKD on dialysis [1][4]. Studies have also explored its effects on other cardiovascular risk factors, such as reducing LDL cholesterol and increasing HDL cholesterol [10].
What patient concerns are associated with sevelamer carbonate?
Patients often have concerns about managing chronic kidney disease and the burden of taking multiple medications with meals. Adherence to sevelamer carbonate, managing its gastrointestinal side effects, and understanding its role in their overall treatment plan are common patient concerns [5].
What are the regulatory approvals for sevelamer carbonate?
Sevelamer carbonate has received approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/sevelamer-carbonate
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/
[7] https://www.drugpatentwatch.com/
[8] https://www.drugpatentwatch.com/
[9] https://www.drugpatentwatch.com/
[10] https://www.drugpatentwatch.com/